The new company, EA Pharma, will be held at 60 % by Eisai and 40 % by Ajinomoto and start operation from April 2016. Products will include Ajinomoto’s branched-chain amino acid formulations, Eisai’s proton pump inhibitors, but also antibodies intended for the treatment of Crohn’s disease which are currently under development
Ajinomoto press release, Oct. 15, 2015
Eisai and Ajinomoto Pharma will launch a joint company focused on GI diseases